Antonio Barberis

Dr. Antonio Barberis

National Research Council - CNR
+1
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 September 2014 in Journal of Food Composition and Analysis
Verified
Journal Article
Closed access
Angela FaddaAngela Fadda
Angela Fadda
MSMaria Serra
Maria Serra
MMMaria Giovanna Molinu
Maria Giovanna Molinu
EAEmanuela Azara
Emanuela Azara
Antonio BarberisAntonio Barberis
Antonio Barberis
Daniele SANNADaniele SANNA
Daniele SANNA


1 July 2003 in Journal of Arid Environments
Verified
Journal Article
Closed access
Antonio BarberisAntonio Barberis
Antonio Barberis
SDS Dettori
S Dettori
MFM.R Filigheddu
M.R Filigheddu


31 March 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
AFAndrea Floris
Andrea Floris
MMMichael Mazarei
Michael Mazarei
XYXi Yang
Xi Yang
ARAaron Robinson
Aaron Robinson
JZJennifer Zhou
Jennifer Zhou
Maria Lauda TomasiMaria Lauda Tomasi
Maria Lauda Tomasi
Existing therapeutic strategies for breast cancer are limited by tumor recurrence and drug-resistance. Antioxidant plant-derived compounds such as flavonoids reduce adverse outcomes and have been identified as a potential source of antineoplastic agent with less undesirable side effects. Here, we describe the novel regulation of fatty-acid synthase (FASN), the key enzyme in de novo fatty-acid synthesis, whereby Vitis vinifera L. cv Vermentino leaf hydroalcoholic extract lowers its protein stability that is regulated by small ubiquitin-like modifier (SUMO)ylation. The phenolic compounds characterization was performed by liquid chromatography–mass spectrometry (LC–MS), whereas mass spectrometry (LC–MS/MS), Western blotting/co-immunoprecipitation (Co-IP) and RT-PCR, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), clonogenicity assays, and FACS analysis were used to measure the expression of targets and tumorigenicity. Vermentino extract exhibits antitumorigenic effects, and we went on to determine that FASN and ubiquitin-conjugating enzyme 9 (UBC9), the sole E2 enzyme required for SUMOylation, were significantly reduced. Moreover, FASN was found SUMOylated in human breast cancer tissues and cell lines, and lack of SUMOylation caused by SUMO2 silencing reduced FASN protein stability. These results suggest that SUMOylation protects FASN against proteasomal degradation and may exert oncogenic activity through alteration of lipid metabolism, whereas Vermentino extract inhibits these effects which supports the additional validation of the therapeutic value of this compound in breast cancer.